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Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related
deaths in Jammu and Kashmir (J&K) region of India. A substantial proportion of esophageal
carcinoma is associated with infection of high-risk HPV type 16 and HPV18, the oncogenic
expression of which is controlled by host cell transcription factor Activator Protein-1 (AP-1). We,
therefore, have investigated the role of DNA binding and expression pattern of AP-1 in esophageal
cancer with or without HPV infection.
Methods: Seventy five histopathologically-confirmed esophageal cancer and an equal number of
corresponding adjacent normal tissue biopsies from Kashmir were analyzed for HPV infection,
DNA binding activity and expression of AP-1 family of proteins by PCR, gel shift assay and
immunoblotting respectively.
Results: A high DNA binding activity and elevated expression of AP-1 proteins were observed in
esophageal cancer, which differed between HPV positive (19%) and HPV negative (81%)
carcinomas. While JunB, c-Fos and Fra-1 were the major contributors to AP-1 binding activity in
HPV negative cases, Fra-1 was completely absent in HPV16 positive cancers. Comparison of AP-1
family proteins demonstrated high expression of JunD and c-Fos in HPV positive tumors, but
interestingly, Fra-1 expression was extremely low or nil in these tumor tissues.
Conclusion: Differential AP-1 binding activity and expression of its specific proteins between HPV
- positive and HPV - negative cases indicate that AP-1 may play an important role during HPV-
induced esophageal carcinogenesis.
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Esophageal squamous cell carcinoma (ESCC) is one of the
most common cancers in the world with extremely poor
prognosis due to late presentation and rapid progression.
It is eighth among the most common cancers worldwide
and fifth most common cancer in developing countries
[1]. ESCC shows a great variation in geographic distribu-
tions and the incidence rates are remarkably higher in dis-
tinct areas such as China, Singapore, Iran, France, South
Africa, Puerto Rico, Chile, Brazil and northern and eastern
Himalayan region. The wide geographical variation in the
incidence reflects strong influence of environmental fac-
tors [2]. This cancer is also a major health problem in
India; particularly in Kashmir valley and is associated with
characteristic food and drinking habits such as drinking of
hot salted tea which contains carcinogenic compounds
like nitrosamines [3]. Besides salted tea, tobacco smoking
(Hukka; local name Jajjer) is also very common in this
area and is a potential risk factor for increased incidence
of esophageal cancer [2,4,5]. Though recent reports have
documented alterations of some oncogenes and tumor
suppressor genes, the exact molecular and genetic basis of
esophageal carcinogenesis still remains poorly under-
stood [6].
Several studies have demonstrated infection of human
papillomaviruses (HPVs) in esophageal cancer world over
[7]. Though prevalence of this virus varies between 10 -
70% from one geographical region to other, the infection
of high risk HPV (HR-HPV) types mainly HPV type 16 and
HPV18 is found to be the most common in almost all
parts of the world [8]. Our earlier study has also demon-
strated that a significant proportion of esophageal cancer
cases from Kashmir region are infected with HR-HPV type
16 [9]. This and other studies [7-9] indicate an oncogenic
role of HR-HPV types in esophageal carcinogenesis. Since
the virus does not have its own transcriptional machinery,
the expression of its two transforming oncogenes, E6 and
E7, depends primarily on availability of host cell tran-
scription factors, particularly the Activator Protein-1 (AP-
1) [10,11]. It has been demonstrated that a point muta-
tion in the AP-1 consensus sequence within the binding
site of upstream regulatory region (URR) of HPV16/18
leads to complete abolition of E6 and E7 gene expression
[12]. Recent study also indicates that HPV infection may
result in reciprocal alteration in AP-1 activity and its com-
position that could affect downstream gene expression
and signaling leading to tumorigenesis of the infected
cells [13] and better prognosis [14]. However, currently
there is no study that defines the role of AP-1 in HPV
induced esophageal carcinogenesis.
Considering the important role of AP-1 in a variety of epi-
thelial cancers in general and those infected with HPV in
particular, the present study has been carried out to inves-
tigate the possible relationship between HPV infection
and expression profile of AP-1 family proteins in associa-
tion with other etiological factors in the development of
ESCC in Kashmir valley.
Methods
Patients and Specimens
A total of 150 tissue specimens comprising of 75 tumor
tissues and 75 corresponding adjacent normal tissues as a
control of ESCC, from 25 cases with no dysphagia and 50
cases of either grade I, II, and III dysphagia as classified
earlier [15], were collected for analysis in the present
study [Table 1]. None of these patients received any pre-
operative radiation or chemotherapy. All samples were
surgically resected and were collected at the Department
of Cardio Vascular and Thoracic Surgery of Sher-I-Kashmir
Institute of Medical Sciences, Soura, Srinagar, Kashmir
(India). Tissue samples were divided into two parts; one
part was sent to histopathological diagnosis and other
half was stored in -70°C for molecular investigations. His-
topathological grades and clinical staging were evaluated
according to standard criteria [16] by two pathologists
independently with 17 cases graded as well-differentiated
squamous cell carcinoma (WDSSC), 45 as moderately-
differentiated squamous cell carcinoma (MDSCC) and 13
as poorly-differentiated squamous cell carcinoma
(PDSCC) whereas 46 patients were scored as stage I & II
and 29 as stage III & IV. Only histopathologically con-
firmed cases were included for molecular analysis. Written
informed consent was obtained from all the subjects
included in the study and was carried out in accordance
with the principles of the Helsinki Declaration. The study
was approved by the Ethics Committee of the Hospital
and the institute.
DNA extraction and PCR detection of HPV
High molecular-weight genomic DNA was isolated from
tumor and normal adjacent tissue specimens by standard
proteinase K digestion and a phenol-chloroform extrac-
tion procedure routinely followed in our laboratory [17].
PCR for detection of HPV16 and HPV18 DNA were car-
ried out as described previously [18], using type-specific
primers [HPV16 (1), 5-AAG GCC AAC TAA ATG TCA C-3;
HPV16 (2), 5-CTG CTT TTA TAC TAA CCG G-3; HPV18
(1), 5-ACC TTA ATG AAA AAC CAC GA-3; HPV18 (2), 5-
CGT CGT TTA GAG TCG TTC CTG-3]. Initially, all DNA
samples were tested for the presence of HPV by using a
pair of consensus primers located within the conserved L1
open reading frame (ORF) of the HPV genome (MY 11, 5-
GCM CAG GGW CAT AAY AAT GC-3; MY 09, 5-CGT CCM
ARR GGA WAC TGA TC-3; where M = A/C, W = A/T, Y =
C/T, R = A/G). PCR was performed in a 25 μl reaction mix
containing 100 ng DNA, 10 mM Tris-HCl (pH 8.4), 50
mM KCl, 1.5 mM MgCl2, 125 μM of each dNTP (dATP,
dCTP, dGTP and dTTP), 5 pmol of each oligonucleotidePage 2 of 13
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investigated from Kashmir region.
Characteristics Subgroup Patients n = 75 (%age)
Gender
Male 43(57)
Female 32(43)
Age
40-60 years Mean age (57.5) 47(63)
>60 years 28(37)
Smoking Status
Smoker 51(68)
Non-smoker 24(32)
Dysphagia
Grade I, II, III 50(67)
No Dysphagia 25(33)
Location of tumor
Upper 10(13)
Middle 60(80)
Lower 5(7)
Clinical Stage
Stage I & II 46(61)
Stage III & IV 29(39)
Histological Grade
WDSCC 17(23)
MDSCC 45(60)
PDSCC 13(17)
Consumption of hot salted tea/day
With sodium bicarbonate 1-3 cups 20 (27)
3-6 cups 38(51)
> 6 cups 10(13)Page 3 of 13
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Biosystems, Foster City, CA, USA). The temperature pro-
file used for amplification constituted an initial denatura-
tion at 95°C for 5 min followed by 35 cycles with
denaturation at 95°C for 30 sec, annealing at 55°C for 30
sec and extension at 72°C for 1 min, which was extended
for 4 min in the final cycle. The oligonucleotide primers
were synthesized in an automated Applied Biosystems
DNA synthesizer (Model 381A; Applied Bio-systems, Fos-
ter City, CA, USA) using the phosphoramidite method
and purified in high performance liquid chromatography
(HPLC).
Preparation of protein extract
Protein extracts from all ESCC biopsies (cancer and nor-
mal adjacent control) were prepared by the method of
Dignam [19] with minor modification described earlier
[14] Briefly, frozen tissues were minced and resuspended
in ice-cold buffer A [20 mM HEPES (pH 7.6), 20% (v/v)
Glycerol, 10 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1
mM DTT, 1 mM PMSF, 2 μg/ml Leupeptin and 10 μg/ml
Aprotinin]. The lysates were microfuged at 4,000 rpm for
10 min at 4°C after incubating them for 15 min on ice.
The supernatant was transferred in a new tube and desig-
nated as cytoplasmic extracts. The pellet containing iso-
lated nuclei was resuspended in the 2 times pellet amount
of extraction buffer B [20 mM HEPES (pH 7.6), 25% (v/v)
Glycerol, 500 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
1 mM DTT, 1 mM PMSF, 2 μg/ml Leupeptin and 10 μg/ml
Aprotinin]. The extraction mixture was microfuged after 1
hr at 14,000 rpm at 4°C for 25 min. The resulting super-
natant was designated as nuclear extract. The concentra-
tion of protein in the extracts was determined by standard
Bradford method (Bio-Rad Laboratories, Inc.CA) and the
extracts were stored at -70°C freezer until use.
Electrophoretic mobility shift assay
For electrophoretic mobility shift assay (EMSA), the fol-
lowing oligonucleotides were used: AP-1 consensus
sequence 5 - CGCTTGATGACTCAGCCGGAA-3 (consen-
sus binding sites are underlined and italicized), and Oct-
1 consensus oligonucleotide 5-TGTCGAATGCAAAT-
CACTAGAA-3. The oligonucleotide probes were synthe-
sized in an Applied Biosystems DNA synthesizer using
phosphoramidite chemistry. The above oligonucleotides
were annealed and labelled with [γ32P] ATP (3,000 Ci/
mmol; Jonaki, Hyderabad, India) by T4 polynucleotide
kinase and gel purified in a 15% polyacrylamide gel [20].
The binding reaction was performed in a 25 μl reaction
volume containing 50% glycerol, 60 mM HEPES (pH
7.9), 20 mM Tris-HCl (pH 7.9), 300 mM KCl, 5 mM
EDTA, 5 mM DTT, 100 μg of BSA per milliliter, 2.5 μg of
poly (dI-dC) and 10 μg of nuclear extract. After 5 min,
10,000 cpm of the [γ32P] ATP 5-end labelled double-
stranded oligonucleotide probe was added and the incu-
bation was continued for additional 25 min at room tem-
perature. For monitoring AP-1 composition in supershift
assays, 2 μg of polyclonal antibodies (Abs) directed
against all the Jun and Fos family members (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) were added and the
reaction mixture was further incubated for 1 hr at 4°C.
The following Abs were used: anti-cJun (epitope corre-
sponding to amino-terminal domain of mouse c-Jun
p39); anti-JunB (epitope corresponding to carboxy termi-
nal domain of mouse JunB); anti-JunD (epitope corre-
sponding to carboxy terminus of mouse JunD); anti-cFos
(epitope corresponding to a highly conserved domain of
cFos p62 of human origin); anti-FosB (epitope corre-
sponding to amino acids within the central domain of the
FosB protein of mouse origin); anti-Fra-1 (epitope corre-
sponding to amino terminus of Fra-1 of rat origin) and
anti-Fra-2 (epitope corresponding to carboxy terminus of
Fra-2 of human origin). The DNA-protein complexes were
resolved on 4.5% non-denaturing polyacrylamide gel,
PAGE (cross-linking ratio, 29:1), dried and exposed over-
night to Phosphoimager (Fuji Film-Fla-5100) or Kodak X-
Omat Films (Kodak India Ltd., India). The quantitative
densitometric analysis was performed on shifted and
super-shifted bands as a percent loss of band intensity
indicating AP-1 binding in reaction having no antibody
using Alpha Ease FC version 4.1.0 (Alpha Innotech Cor-
poration. IL)
Without sodium bicarbonate 7(9)
HPV status
Tumor Tissues HPV L1 Positive 14 (19%)
HPV16 14 (100%)
Other HPVs Nil
Normal Adjacent Tissues HPV L1 Positive Nil
Table 1: Clinico-pathological and demographic characteristics and HPV status of Esophageal Squamous Cell Carcinoma cases 
investigated from Kashmir region. (Continued)Page 4 of 13
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Protein extracts (50 μg of protein per lane) were resolved
in 10% polyacrylamide gel, electrotransferred to Immo-
bilon-P membranes (Millipore Corporation, Bedford,
MA), and probed with polyclonal rabbit antibodies of the
corresponding family members of AP-1 as indicated in
previous section. The incubation was carried out over-
night in PBS supplemented with 5% skim milk powder,
0.05% Tween 20 (Sigma-Aldrich, CHEMIE GmbH, Ger-
many), and different dilutions of respective antibodies.
The bands were visualized with anti-rabbit immunoglob-
ulin G (IgG) antibody conjugated with horseradish perox-
idase using the Amersham ECL™ western blotting
detection reagent kit (GE Healthcare). The blots were
stripped and re-probed for β-actin levels to confirm equal
loading and normalization. The expression levels of dif-
ferent AP-1 members were evaluated by densitometry
using Alpha Digidoc version 4.1.0 (Alpha Innotech Cor-
poration, IL) on a scale of 0-255 and the averaged pixel
values were re-grouped for analysis on an arbitrary scale as
strong => 50%; medium = 10-50%; weak = 1-10% and
nil/not detectable < 1% as described earlier [21].
Statistical Analysis
Statistical analysis on the data was performed using Epi-
Info version 6.0 software (Center of Disease Control and
Prevention, Atlanta, USA) and SigmaPlot version 10.0
(Systat Software, Point Richmond, CA). The association
between HPV infection and expression profile with dis-
ease severity and clinico-pathological parameters was
determined using the Fischer's Exact Test or Chi Square
and Students t-test in order to compare the fold change of
AP-1 binding between HPV positive and HPV negative
ESCC cases. These tests were considered statistically signif-
icant when p ≤ 0.05.
Results
A total of consecutive 75 surgically resected and his-
topathologically confirmed esophageal tumors along
with corresponding normal adjacent tissues were ana-
lyzed to study the activity and expression of AP-1 in rela-
tion to HPV infection. Various clinico-epidemiological
characteristics of esophageal squamous cell carcinoma
cases from Kashmir valley and the status of their HPV
infection is presented in Table 1. The cases investigated
had slightly higher male representation (male to female
ratio 1:0.74) with an average age of 57.5 years. With
respect to tobacco consumption, 68% of the patients had
smoking history and 67% of cases demonstrated various
grades of dysphagia. Clinically, 39% cases had late presen-
tation in either stage III or stage IV. Histopathologically,
60% of cases belonged to moderately differentiated squa-
mous cell carcinoma Table 2. Patient stratification with
respect to consumption of hot-salted tea containing
sodium bicarbonate which is considered as a potent car-
cinogen in local Kashmiri population revealed consump-
tion of three or more cups of salted tea per day by more
than two third of the patient group.
Prevalence of Human Papillomavirus infection in ESCC
Since HPV is considered as one of the important risk fac-
tor in esophageal carcinogenesis, tissue samples were
screened by PCR for HPV infection using HPV
L1consensus primers (Figure 1A), which revealed pres-
ence of HPV infection in 14 out of 75 tumor biopsies
(19%) whereas, no HPV could be detected in any of the
normal adjacent tissues. Subsequent PCR- based HPV typ-
ing using type-specific primers revealed that all 14 HPV L1
positive esophageal tumors were infected with HPV type
16 (Figure 1B). None of the HPV-infected esophageal
tumors showed co-infection with other high- risk/low-risk
HPV types.
To determine cofactors that may increase the risk of HPV
infection in esophageal cancer, association of HPV infec-
tion with various clinico-pathological and demographic
characteristics was examined [Table 2]. Majority of HPV
infection was confined to patients with smoking history
(p = 0.03) or having any grade (I, II or III) of dysphagia. A
higher occurrence of HPV infection was also detected in
advanced stage of cancer, both clinically (stage III and
stage IV; p < 0.03) as well as histologically (WDSCC and
PDSCC; p < 0.02). Most interestingly, more than 50% of
HPV infection was confined to patients who were in
poorly-differentiated state of the disease. Infection of HPV
did not show any association with sex, age, or location of
the tumor.
Constitutive activation and DNA binding activity of AP-1 
in ESCC in the absence or presence of HPV infection
To investigate the role of AP-1 in epithelial carcinogenesis,
we analyzed the status of AP-1 DNA binding activity by
gel shift assay in esophageal tumors and compared it with
that of normal adjacent tissues. As shown in Figure 2A, the
presence of constitutively active AP-1 DNA binding activ-
ity was detected in most of the esophageal tumors
whereas, it was undetectable or very low in all correspond-
ing normal adjacent tissues. Densitometric analysis of the
shifted AP-1 band revealed variability in the degree of
binding/activation in different cases ranging from 3 to 8
fold increase with respect to normal tissues. The specificity
of AP-1 binding activity was confirmed by re-testing the
samples for Oct-1 which is ubiquitously active in all cells
and was used as an internal control by performing cold
competition assay with 100-fold molar excess of homolo-
gous AP-1 and a heterologous Oct-1 cold probe (Figure 2B
and 2C). In order to examine if HPV infection has any
effect on AP-1 binding activity in esophageal cancer, as
depicted in representative photograph in Figure 3A, we
observed a differential activation of AP-1 in ESCC; an ele-Page 5 of 13
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in HPV-positive tumors as compared to that in HPV-neg-
ative tumor tissues. These observations were reconfirmed
by densitometric evaluation of gel shifted bands that
showed significantly higher (p < 0.05) AP-1 binding activ-
ity in HPV-positive tumors than that of HPV-negative
tumors (Figure 3B).
Composition of functional AP-1 complex in HPV-negative 
and HPV-positive esophageal squamous cell carcinoma
Since functional AP-1 complex is constituted either by
homo or hetrodimerization between different members
of Jun and Fos family of proteins, we analyzed the compo-
sition of AP-1 complex in esophageal tumor tissues both
in the presence and absence of HPV infection in a gel
Table 2: Association of Human Papillomavirus infection with clinicopathological, and other characteristics of ESCC cases
Characteristics (n = 75) %age HPV+Ve (n = 14) (%) p-value
Sex 0.22
Male (n = 43) 57 6(14)
Female (n = 32) 43 8(25)
Age 0.89
40-60 years (n = 47) 63 9(19)
>60 years (n = 28) 37 5(18)
Smoking Status 0.03
Smoker (n = 51) 68 13(25)
Non-smoker (n = 24) 32 1(4)
Dysphagia 0.03
Grade I, II & III (n = 50) 67 13(26)
No Dysphagia (n = 25) 33 1(4)
Location of tumor 0.37
Upper (n = 10) 13 1(10)
Middle (n = 60) 80 13(22)
Lower (5) 7 -
Clinical Stage 0.03
Stage I & II (n = 46) 61 5(11)
Stage III & IV (n = 29) 39 9(31)
Histological Grade 0.020
WDSCC (n = 17) 23 2(12)
MDSCC (n = 45) 60 6(13)
PDSCC (n = 13) 17 6(46)Page 6 of 13
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members of AP-1 e.g. cJun, JunB, JunD, cFos, FosB, Fra-1
and Fra-2 (Figure 4A &4B). The supershift analysis
revealed a preferential hetrodimerization between cFos
and JunB instead of its canonical dimerization partner
cJun which did not participate in AP-1 complex formation
although it showed up-regulated expression in western
blotting both in HPV positive as well as HPV negative
tumors. In majority of HPV negative tumors more than
85% (53/61) of the supershifts had a JunB participation.
Among the Fos family of proteins; mainly cFos was found
to be the major contributor but Fra-1 also showed a minor
participation as revealed in band supershift assays. No
other Jun or Fos family members showed up in supershift
assay (Figure 4B). On the other hand, HPV16-infected (n
= 14) tumors also showed major participation of JunB and
cFos but the most interesting observation was an exclusive
participation of JunD in more than 70% of cases (10/14).
In contrast, Fra-1 was completely absent in functional AP-
1 activity (Figure 4A). In both HPV-positive and HPV-neg-
ative tumors cFos was the major partner contributing
more than 90% participation in the DNA binding activity.
Expression of AP-1 family proteins in esophageal 
squamous cell carcinoma in presence or absence of HPV 
infection
Western blotting experiments were performed to analyze
the pattern and level of expression of all AP-1 family pro-
teins (cJun, JunB, JunD, cFos, FosB, Fra-1 & Fra-2) in ESCC
cases. Most of the AP-1 family members showed differen-
tial expression pattern in esophageal carcinoma tissues
compared to their adjacent normal counterparts. While a
very low or negligible expression of cJun, JunB, JunD,
cFos, FosB, Fra-1 and Fra-2 was observed in normal adja-
cent tissues, the majority of them showed significantly ele-
vated expressions in tumor tissues (Table 3 and Figure 5).
In view of the impact of HPV infection on the binding
activity and composition of functional AP-1 complex, we
examined the expression pattern in HPV-positive and
HPV-negative tumors. As shown in Figure 5 and Table 4,
we observed a higher level of expression of JunD and cFos
in HPV infected cases. Though the expression pattern of
other members was higher, there was no significant
change in expression pattern of these proteins with respect
to HPV infection. Interestingly, unlike in other cancers,
Fra-1 expression was diminished or completely lost in
tumor tissues infected with HPV16 while HPV-negative
tumors showed a very high expression of Fra-1 and also
participates in DNA binding as revealed by supershift
assay. The higher expression pattern of JunB, JunD, cFos
are in concordance with gel shift assays that showed the
participation of these proteins in AP-1 complex forma-
tion.
Discussion
Although AP-1 has been demonstrated to play a crucial
role in HPV - induced carcinogenesis and oncogenic HR-
HPVs have been detected in a sizable number of ESCC,
there is no study that describes the role of AP-1 in ESCCs.
In the present study, we demonstrate for the first time,
constitutive activation of AP-1 in ESCCs and change in
binding partners that form active AP-1complex in ESCCs.
ESCC with HPV infections constituted a significant pro-
portion (19%; 14/75) and interestingly all these cases har-
bored the most prevalent high-risk HPV type 16.
Constitutive activation of AP-1 leading to its high binding
activity was observed in most of the esophageal tumors,
irrespective of their clinical stage and histo - pathological
grade; whereas normal adjacent tissues showed low or no
AP-1 activation. Aberrant AP-1 activity is one of the most
frequent mechanisms of tumor promotion in epithelial
tissues irrespective of the tumor site and is mediated
through activation of its upstream kinases such as ERK,
JNK and p38 [22]. Similar to our observation, constitu-
tively active AP-1 has also been observed in other epithe-
lial cell malignancies [21,23-25]. But the mechanism(s)
by which AP-1 or its upstream regulatory kinases get acti-
vated in ESCC is not known. Apart form physiological reg-
(A&B): Detection of HPV infection by PCR in ESCC cases from Kashmir regi nFigure 1
(A&B): Detection of HPV infection by PCR in ESCC 
cases from Kashmir region. Panel A, Representative 
ethidium bromide-stained 2% agarose gel showing presence 
of HPV infection in esophageal cancer as indicated by appear-
ance of L1 consensus primer-generated amplimer of 450 bp 
along with amplification of 268 bp fragment of β-globin gene 
that was used as PCR internal control. Panel B, shows type-
specific amplification of HR-HPV type 16 (217 bp) in HPV L1 
positive samples of ESCC. P = positive control 
(HPV16DNA), N = negative control (Placental DNA), B = 
Blank, Lanes 1 to 12 are DNA samples from esophageal 
tumor biopsies, M = φX174 HaeIII-digested molecular weight 
marker.
M   P    N     1     2     3    4    5    6     7    8     9    10  11   12   B
M          P            N           4             7            8              10
450 bp
268 bp
217 bp
A
BPage 7 of 13
(page number not for citation purposes)
BMC Cancer 2009, 9:329 http://www.biomedcentral.com/1471-2407/9/329ulators like growth factors, cytokines or hormones, AP-1
activity is also induced by bacterial and viral infections as
well as many carcinogens [26]. Recent study showed that
HPV which is found in almost all cervical cancer, can also
promote AP-1 activation to a significant level [13,21].
Apart from HPV, other infections such as H. pylori, preva-
lence of which is notably high in Kashmir region, are also
known to induce AP-1 activation [27]. Another factor that
could significantly contribute to constitutive activation of
AP-1 is consumption of sodium-bicarbonate-brewed hot
salted tea which is very widely consumed by majority of
people in snow-capped Kashmir Valley [28]. This salted
tea it is rich in carcinogenic N-nitroso compounds [3] that
primarily act through AP-1 [11]. Interestingly, majority of
ESCC cases investigated in the present study showed AP-1
activation had a high intake of salted tea.
Functional AP-1 complex is constituted either by homo-
or hetero-dimerization between different members of Jun
and Fos family of proteins [25]. Our results demonstrate
a preferential participation of JunB and c-Fos in active AP-
1 complex formation in almost all tumors irrespective of
HPV infection. Interestingly, HPV positive tumors dem-
onstrated an additional participation of JunD in AP-1
DNA binding complex. Also, Fra-1 which showed minor
participation in HPV negative tumors was completely
absent in HPV positive cases. Apart from formation of het-
erodimer between Jun and Fos proteins, homodimeriza-
(A-C): Bandshift assays showing constitutive activation and DNA binding specificity of AP-1 in esophageal cancerFigure 2
(A-C): Bandshift assays showing constitutive activation and DNA binding specificity of AP-1 in esophageal can-
cer. (A) nuclear proteins (10 μg) extracted from esophageal tumors (1-5) and their adjacent normal tissues were incubated 
with γ32P-labeled double stranded AP-1 binding probe and run on 4.5% non-denaturing PAGE. (B) uniform binding of Oct-1 in 
normal adjacent tissues and cancer. (C), binding specificity of AP-1 in esophageal cancer biopsies was evidenced by adding 100× 
molar excess of unlabeled homologous competitor, AP-1 oligo in competition with heterologous probe Oct-1 as indicated in 
methods. Arrows indicate the position of specific retarded bands.
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complex but complete absence of cJun in supershift assays
indicate that cJun do not participate in functional AP-1
complex formation and hence no jun homodimer forma-
tion takes place in ESCC. It is interesting to note here that
though c-Jun showed elevated expression in western blot-
ting (see Figure 5), it does not participate in DNA binding
activity. It is quite possible that even if a protein is overex-
pressed, it may not always participate in DNA binding
activity and trans-activation possibly due to mutation
within the binding sites or otherwise. It can also be spec-
ulated that in addition to posttranslational modifications
of c-Jun, a simple competition with JunB [29] and JunD to
bind with cFos, may also account for the exclusion of cJun
from AP-1 complex in esophageal cancer. It is interesting
to note that presence of active JunB/cFos dimers may pro-
vide a favorable niche for establishment of HPV infection
and viral propagation as two AP-1 binding sites are
present in URR of HPV18 that essentially require JunB
containing hetrodimers for HPV transcription [12]. These
observations, therefore, indicate presence of suitable co-
operativity between the virus and the host for expression
of viral oncogenes.
Most of the ESCC tissues irrespective of their clinical and
histopathological grade showed a high expression of AP-1
family of proteins in tumor tissues as compared to their
normal counterparts. Upregulated AP-1 activity is fre-
quently associated with overexpression of its family mem-
bers [30,31]. Since majority of AP-1 members are part of
immediate early response genes and express differentially
in non-neoplastic and neoplastic tissues as well as con-
tribute both in early events of tumorigenesis and tumor
progression [30,31], elevated AP-1 expression and activity
appears to be generic carcinogenesis-associated event.
Though it is well established that AP-1 regulates the
expression of HPV oncogenes [10], recent observations
indicate that HPV reciprocally modulate AP-1 expression
and its activity [13]. We stratified expression levels of AP-
1 which revealed a differentially higher expression of
(A&B): Gel shift analysis showing levels of active AP-1 DNA binding complexes present in HPV-positive and HPV-negative esophagea cancer biop iesFigure 3
(A&B): Gel shift analysis showing levels of active AP-1 DNA binding complexes present in HPV-positive and 
HPV-negative esophageal cancer biopsies. (A) γ32P-labelled double stranded AP-1 oligonucleotides were co-incubated 
with 10 μg of nuclear protein extracts from HPV16 positive (C1), HPV negative (C2) esophageal tumor biopsies and corre-
sponding normal adjacent tissues (N1, N2), analyzed on a 4.5% PAGE. The intensities of the bands were quantified as indicated 
in methods. Nuclear extracts of HeLa cells, which constitutively express active AP-1, was used as positive control. (B) Mean 
fold change in AP-1 binding activity in HPV negative and HPV positive esophageal cancer with respect to normal adjacent con-
trol tissues. Error bars indicate standard deviation, p-value 0.02 as compared to HPV negative tumor tissue. Arrows indicate 
the position of specific retarded bands.
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BMC Cancer 2009, 9:329 http://www.biomedcentral.com/1471-2407/9/329JunD and cFos proteins in HPV-positive tumors, whereas
Fra-1 levels were characteristically low or nil in them. Fra-
1 was, however, highly expressed in HPV- negative
tumors. Over-expression of Fra-1 and cFos have been
demonstrated in esophageal cancers in some sporadic
studies [32,33]. On the contrary, an in vitro study demon-
strated increase of cFos in HPV16-transformed cell lines is
associated with decreased expression of its negative regu-
lator Fra-1 as well as their reduced contribution in active
DNA-binding activity [13]. In an ingenious experiment,
overexpression of cFos in HPV 18 positive non-tumori-
genic HeLa - Fibroblast hybrid 444 cells having low or no
cFos but a very high amount of Fra-1 expression resulted
in tumorigenic cells which showed complete loss of Fra-1
but a high expression of cFos [34]. These observations per-
fectly match with in vivo situations in HPV-infected
esophageal tumors, where Fra-1 expression was dimin-
ished or completely absent. These observations, therefore,
indicate a potential antagonistic effect of HPV infection
on Fra-1. Fra-1 have been proposed to have tumor sup-
pressor function as it is located in chromosome 11q13
region which is known to harbor tumor suppressor genes
[35] and its over-expression have recently been shown to
inhibit cell proliferation, induce apoptosis and reduce
tumorigenesity [36]. Moreover, change in AP-1 composi-
tion resulting in elimination of Fra-1 has been found to be
associated with enhanced tumorigenesity [13,34]. Thus,
lack of Fra-1 appears to contributing to more aggressive-
ness of the disease, as majority of these patients were
infected with HPV and in poorly-differentiated state. This
is in sharp contrast to our recent observation in oral can-
cer, where presence of HPV but lack of Fra-1 expression
(A&B): Band supershift assay showing composition of AP-1 complexes in HPV positive and HPV negative esophageal cancerFigure 4
(A&B): Band supershift assay showing composition of AP-1 complexes in HPV positive and HPV negative 
esophageal cancer. 10 μg of nuclear protein extracts from HPV16-positive (A) or HPV-negative (B) ESCC biopsies were co-
incubated with γ32P-labeled double stranded AP-1 probe. Oligonucleotides and specific antibodies (2 μg each) to all AP-1 family 
proteins as indicated and analyzed on a 4.5% PAGE. The intensities of the shifted and super-shited bands were quantified. 
Supershift was calculated as a percent loss of band intensity indicating AP-1 binding in reaction having no antibody.
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BMC Cancer 2009, 9:329 http://www.biomedcentral.com/1471-2407/9/329was observed mainly in well-differentiated oral squamous
cell carcinomas that showed better prognosis [37]. Thus,
it appears that the role of Fra-1 as a tumor suppressor or
oncogene may vary from tumor to tumor and on host-
virus interactions.
Considering oncogenic role of HPVs [38] and their co-
operative interaction with AP-1 signaling [10,13], infec-
tion with HPV has been implicated as a possible etiologi-
cal factor in the development of squamous cell carcinoma
of the esophagus. Our results demonstrated unlike cervi-
cal cancers where HR-HPV infection is an essential etio-
logical factor, the percentage of cases with HPV infection
in ESCC was small and accounted for about one fifth of
total cases. Occurrence of HPV infection in esophageal
cancer is variable and conflicting, ranging from complete
absence to detection of up to 60 to 70% mainly of high -
risk HPV types 16 and 18 [8,39]. Our earlier study on dif-
ferent subset of samples from the same region showed
similar frequency of HPV16 infection [9]. Though consid-
Table 3: Expression profile of AP-1 proteins in immunoblotting and densitometric analysis of their level of expression in normal 
adjacent controls and tumor tissues of ESCC.
AP-1 Family Member Protein Normal
(n = 75)
Cancer
(n = 75)
p-value
Nil Weak Medium Strong Nil Weak Medium Strong
cJun 10 23 42 - - 5 24 46 0.001
JunB 49 16 8 2 2 9 30 34 0.001
JunD 53 20 2 - - 7 21 47 0.001
cFos 69 6 - - - - 13 62 0.001
FosB 4 8 36 27 2 14 29 30 0.52
Fra-1 35 12 19 9 11 17 10 37 0.003
Fra-2 5 5 28 37 11 16 18 30 0.002
Arbitrary level of expression in Immunoblotting: strong =>50%; medium = 10-50%; Weak = 1-10%; and Nil/undetectable =< 1%. Statistical 
calculation was done by grouping nil & weak, medium & strong together. Yates corrected chi-square/Fishers exact test were performed.
Table 4: AP-1 protein expression profile and their densitometric analysis in HPV negative and HPV positive cases of ESCC.
AP-1 Family Member Protein HPV negative Cases
(n = 61)
HPV positive Cases
(n = 14)
p value
Nil Weak Medium Strong Nil Weak Medium Strong
cJun - 5 20 36 - - 4 10 0.6
JunB 2 8 26 25 - 1 4 9 0.64
JunD - 7 19 35 - - 2 12 0.41
cFos - - 13 48 - - - 14 ND
FosB 2 13 23 23 - 1 6 7 0.2
Fra-1 - 14 10 37 11 3 - - 0.001
Fra-2 8 10 15 28 3 6 3 2 0.03
Arbitrary level of expression in Immunoblotting: strong =>50%; medium = 10-50%; Weak = 1-10%; and Nil/undetectable =< 1%. Statistical 
calculation was done by grouping nil & weak, medium & strong together. Yates corrected chi-square/Fishers exact test were performed.Page 11 of 13
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BMC Cancer 2009, 9:329 http://www.biomedcentral.com/1471-2407/9/329erable proportions of esophageal cancers have been
shown to have HPV infection and that too of high risk
types, the etiological role of HPV in these cancers is not
established. It is suggested that HPV infection when
present may act as a co-factor or have synergistic effects
with environmental carcinogens in the genesis of ESCC
and/or their progression. We also demonstrate a signifi-
cant correlation of HPV infection with smoking habit and
intake of nitrosated compounds in salted tea [Table 2].
The entry of HPV in esophageal cancers appears to be in
later stages as the infection was more prevalent in clini-
cally advanced tumors. Therefore, HPV may significantly
influence the disease progression rather than initiation. In
contrast to genital cancers, it has been shown that HPV
infection may be associated with better prognosis [14] as
it is found more in well-differentiated squamous cell car-
cinomas of the head and neck [40] and may positively
influence the treatment outcome [41]. Therefore, determi-
nation of HPV status in esophageal cancer may also be
helpful in predicting the treatment outcome.
Conclusion
Present investigation provides evidence of a constitutively
activated AP-1 in esophageal cancers and demonstrates
involvement of JunB, JunD and cFos as major DNA bind-
ing partners whereas it clearly negates the role of canoni-
cal AP-1 partner, cJun. Expression of AP-1 proteins and
their DNA-binding activity was found to differ between
HPV positive and HPV negative tumors. Considering that
HR-HPV infection causes better prognosis in head and
neck cancers, present findings may provide clue(s) for bet-
ter understanding of HPV-mediated esophageal carcino-
genesis and development of treatment strategies.
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